Nanomix (Nanomix) Interest Expense : $-4.11 Mil (TTM As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Nanomix Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nanomix's interest expense for the three months ended in Dec. 2022 was $ -1.16 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2022 was $-4.11 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nanomix's Operating Income for the three months ended in Dec. 2022 was $ -1.86 Mil. Nanomix's Interest Expense for the three months ended in Dec. 2022 was $ -1.16 Mil. Nanomix did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nanomix Interest Expense Historical Data

The historical data trend for Nanomix's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Interest Expense Chart

Nanomix Annual Data

Trend

Dec20

Dec21

Dec22

Interest Expense

-1.29

-2.22

-4.11

Nanomix Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Interest Expense	Get a 7-Day Free Trial						-0.81	-0.85	-1.02	-1.08	-1.16

Nanomix Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.11 Mil.

Nanomix (OTCPK:NNMX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nanomix's Interest Expense for the three months ended in Dec. 2022 was $-1.16 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-1.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2022 was $10.11 Mil.

Nanomix's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

Nanomix did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Nanomix (Nanomix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2121 Williams Street, San Leandro, CA, USA, 94577

Website

https://www.nanomixdx.com

Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.

Executives

Chris Hetterly	officer: Chief Financial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener	director, 10 percent owner	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger	director, officer: CEO	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney	officer: Chief Operating Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky	officer: Chief Commercial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson	director, officer: CEO and President	BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman	director	1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham	officer: Chief Operating Officer	C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch	director, officer: CEO
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng	director	ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia	officer: Chief Financial Officer	PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin	director	C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome	officer: Chief Operating Officer (3)	178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz	director	33 KACHAL STREET, LEHAVIM L3 85338